

Therapeutic activity of sarpogrelate, and dopamine D2 receptor agonists on cardiovascular and renal systems in alloxan-induced diabetic rats

Mohamed Fouad (✉ Mafrec10@yahoo.com)

Batterjee Medical College for Sciences and Technology <https://orcid.org/0000-0001-6291-6784>

Hekma A. Abd El Latif

Cairo University Faculty of Pharmacy

May Galal

Cairo University Faculty of Pharmacy

Mohammed El Yamani

Cairo University Faculty of Pharmacy

Sherifa Hassaneen

National Organization for Drug Control and Research

Raneem Masoaad

Batterjee Medical College for Sciences and Technology

Research article

Keywords: Cardiovascular, diabetic nephropathy, myocardial injury, TNF α 1, Dopamine receptors

Posted Date: July 30th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-44926/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background Dopamine D₂ agonists are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia. An affiliation showed between the enlistment of myocardial injury ailment and long haul treatment with dopamine D₂ agonist drugs identified with the partial initiation of 5-HT 2a receptors.

Methods The investigation aims to represent the activity of sarpogrelate, a particular 5-HT (2A) receptor blocker, in diminishing myocardial injury prompted by extended haul utilization of D₂ agonist drugs in diabetic rodents. Both bromocriptine and cabergoline managed independently and combined with sarpogrelate for about a month to diabetic nephropathy rats.

Results Bromocriptine and cabergoline created a significant reduction in BGL, BP, and kidney hypertrophy index in diabetic nephropathy rats. Administration of bromocriptine, cabergoline, alone, or in combination with sarpogrelate fundamentally diminished blood concentrations of ALP, AST, urea, and creatinine. Bromocriptine and cabergoline alone showed noteworthy ascending of LDH-1, Troponin I, and TNF α 1 levels in the serum ($p < 0.05$). Paradoxically, utilizing bromocriptine and cabergoline with sarpogrelate treatment altogether diminished the degree of the myocardial biomarkers in the serum. A mix of bromocriptine or cabergoline with sarpogrelate diminished the level of the myocardial infarct size in the heart assessed utilizing the TTC staining method.

Conclusions The examination exhibited that both bromocriptine and cabergoline could be utilized securely in blend with sarpogrelate for a long duration of treatment for diseases like hypertension and diabetes.

Background

Regarding the various varieties of diabetes progress complications, diabetic nephropathy is the foremost well-known renal difficulty and also the foremost source of end-stage renal disease. During the later phases of diabetic nephropathy, transforming growth factor- β 1 overexpression, extracellular matrix deposition, and loss of glomerular structure define glomerulosclerosis [1]. Hyperglycemia is the primary factor for the progress of diabetic nephropathy [2]. It's been demonstrated in several in vitro studies of STZ-induced diabetic nephropathy where serious glucose-induced renal damage is claimed to excessive production of reactive oxygen species (ROS) under hyperglycemic conditions [3, 4, 5]. Bromocriptine is a sympatholytic dopamine D₂ agonist that has been approved for treating type 2 diabetes without risk of hypoglycemia because there is no insulin secretion. Supported previous studies stated bromocriptine administration believed to strengthen low hypothalamic dopamine levels and inhibit excessive sympathetic tone within the central system, leading to a reduction in post-meal plasma glucose levels because of enhanced suppression of hepatic glucose production [6, 7]. Agonists working on dopamine D₂ receptors can lower sign of hypertension by inhibition of Na/k ATPase activity, vasodilation, and

sympathetic nerve activity inhibition. Bromocriptine may secure against I/R injury of the kidney utilizing p44/42 mitogen-initiated protein kinase actuation [8] and preventing chronic nephropathy [9].

Conversely, the bromocriptine-actuated hypotension was wholly nullified by pretreatment with metoclopramide, a dopamine D2 receptor antagonist that crosses the barrier [10, 11]. However, the use of D2 agonists is often related to cardiovascular complications, including hypotension and myocardial disorder. There is an on the spot relationship between the utilization of D2-like R agonist in patients with Parkinson's disease and cardiopathy, especially in the early phase of therapy [12]. D2 receptors are pleiotropic receptors having multiple effects in that activating them inhibits adenylyl cyclase, resulting in inhibition of voltage-gated calcium ions and activation of potassium conductance [13]. Early studies suggested that anterior pituitary hyperplasia correlated with hypersecretion of prolactin [14]. The use of D2 receptor agonists resulted in a reduction in tumor mass.

It demonstrated that long term use of bromocriptine therapy was associated with an increased risk of developing heart disease, which occurred in a cumulative dose-dependent treatment [15]. Dopamine D2 receptor agonists classified as ergot dopamine D2 agonists and non-ergot D2 agonists. Bromocriptine and cabergoline (ergot derivative) are related to valvular cardiopathy since the two drugs have both dopamine D2 and serotonin 5-HT (2A) receptors agonistic activities. Pramipexole (non-ergot derivative) shows few incidences of heart disease onset since it is no effect on 5-HT (2B) receptors [16, 17, 18]. Both sarpogrelate and ketanserin (selective 5HT2a/2b antagonists) constrict cardiac brokenness, infarct size, and changes within the ECG because of MI. Likewise, these outcomes bolster the view that serotonin and 5-HT (2A) may augment the harmful impacts of ischemic injury within the heart [19, 20]. Sarpogrelate found to possess beneficial impacts in peripheral vascular sickness, restenosis after coronary stenting, pneumonic hypertension, intense and relentless myocardial localized necrosis [21]. The current study aims to identify the possible protective effect of sarpogrelate, a 5-HT (2A) receptor blocker, associated with long term use of D2 agonist drugs therapy on cardiac and renal functions in diabetic nephropathy model rats.

Methods

Materials

Sarpogrelate obtained from Shanghai Linebon Ltd. Shanghai, China. Bromocriptine was from Novartis, Italy. Cabergoline was from Pfizer, Italy. Domperidone was from Jamjoom pharmaceutical company, KSA. Alloxan obtained from Sigma-Aldrich (St Louis, MO, USA). Urea; Creatinine; Alkaline Phosphatase; Aspartate Aminotransferase Activity; LDH-1 assay kits; and TNF alpha ELISA Kit obtained from Abcam company. Troponin I test kit from Encode Medical Engineering Company. 2,3,5-Triphenyltetrazolium chloride from Gold Biotechnology, USA.

Animals

Wister albino male rats 5–7 weeks of *age weighing 150–200g* obtained from the animal house of Batterjee medical college. The animals were housed three per cage under controlled standard laboratory conditions in monitored ventilated cages and spontaneously given food and water. The steps of the research were approved by the ethical committee of research of Batterjee medical college. Tutelage was taken, particularly with relevant housing conditions, to avoid or minimize the animals' discomfort. The animals kept on solid floored cages with a deep layer of sawdust, and cages changed daily. Three laboratory technicians administered the treatment, and two investigators collected the data randomly. Data was coded prior to analysis so that the treatment group cannot be identified before analysis is completed. At the end of the study, all animals were euthanized by thiopental (intravenous injection, 150 mg/kg) for tissue collection.

Induction of diabetes by alloxan

Alloxan monohydrate dissolved in sterile normal saline. Diabetes was induced in 30 rats (150-200 g) by a single intraperitoneal injection of alloxan (5%) 150 mg/kg. The rats kept fasting for 12 h before the injection of alloxan. Fasting plasma glucose measured by obtaining tail blood samples. The rats which showed a plasma glucose level of 200 mg/dl or more were considered diabetic and taken in the study [22].

Experimental design

Tests took place four weeks after the induction of diabetes. The rats divided randomly into six diabetic groups and one healthy control group, each group of 6 rats. The sampling calculation is done based on resource equation method [23]. Once there was a stable rising in the urea and creatinine levels in the blood, drugs injected.

1. The normal control group (Saline, IP)
2. Diabetic control group (Saline, IP)
3. Diabetic group treated with bromocriptine (4 mg/kg, IP)
4. Diabetic group treated with cabergoline (0.6 mg/kg ,IP)
5. Diabetic group treated with sarpogrelate (50 mg/kg, IP)
6. Diabetic group treated with a combination between bromocriptine and sarpogrelate by the same doses.
7. Diabetic group treated with a combination between cabergoline and sarpogrelate by the same doses.

Determination of blood glucose level

Blood glucose levels tested on the 0 day, 1st, 7th, 14th, and 21st days from the start of the experiment. Blood samples collected from the tail of the fasting animals. One millimeter of its end cut and a drop of

blood used for blood glucose tests using an advanced glucometer (Roche, USA). The accuracy of glucometer checked with the O-toluidine method [24].

Blood Pressure Recording

Basal blood pressure was measured employing a non-invasive blood pressure recorder apparatus (Ugobasile instruments, Italy).

Each rat placed in an exceeding restrainer and appropriate cuff sensor mounted on its tail and warmed to about 33- 35 °C. The tail cuff was inflated to a pressure above 200 mmHg, systolic blood pressure; diastolic blood pressure was measured directly by the tail-cuff and pulse sensor two hours after treatment of drugs [25].

Estimation of liver & kidney functions

Alkaline phosphatase and aspartate aminotransferase activities determined using the method described by King and King (1954) [26]. The procedure of Tietz et al. (1994) [27] used to determine serum creatinine concentration, while the serum urea concentration determined by the method of Kaplan (1965) [28]. After the end of the study, the kidneys washed with normal saline and weighed. The kidney hypertrophy index calculated by determining the kidney weight and body weight ratio (g/g) $\times 10^3$.

Estimation of serum biomarkers of myocardial injury

The blood was withdrawn through the retro-orbital venous plexus method, kept at 37°C for 30 mins, and centrifuged at 4°C, 3000 rpm for 10 mins. Then the separated serum stored at -20°C for various biochemical analyses. The severity of the cardiac injury assessed by the estimation of lactate dehydrogenase (LDH-1) and cardiac troponin I (cTnI) in serum. LDH-1 and troponin levels analyzed by spectrophotometric methods using commercially available diagnostic kits consistent with the methods of Nieland, 1955 [29].

Serum TNF- α 1 concentrations

Serum TNF-alpha cytokines level was identified by the ELISA technique using a quantitative sandwich enzyme immunoassay technique (Abcam Company). The test was done according to the company's instructions. The ELISA reader (optical density at 405nm immediately) calculated and applied on a standard curve to sort out the concentration of the cytokines.

Evaluation of Myocardial Infarct Size by TTC

For evaluation of the myocardial infarcted area, the hearts were removed, washed in phosphate-buffered saline, frozen and stored at -20°C, the frozen hearts sliced into 1 mm sections along the long axis from apex to base. Triphenyl tetrazolium chloride (TTC) staining accustomed to assess myocardial tissue viability and determine myocardial infarction size. The tissue slices incubated in 1% TTC PBS solution,

pH 7.4, at 37°C for 20 min. Tissues fixed in 10% PBS-buffered formalin overnight at 2°C–8°C. Either side of every TTC-stained tissue slice was photographed with the photographic camera to differentiate the red-stained viable and also the white-unstained necrotic tissues [30]. Digital photographs downloaded to a computer. Areas stained in white and red were measured using SigmaScan software (SPSS Science) in trace-measurement mode. That mode was used to measure either the ischemic or the infarcted areas, which may be a sum of calibrated pixels during a defined region. This was done manually by drawing an image layer on the photograph [31]. The following equation calculated the infarction size percentage:

The percentage of Infarct volume = Infarct volume / Total volume of slice X 100

Statistical analysis

The data and statistical analysis done comply with the recommendations on experimental design and analysis in pharmacology [32]. The results expressed as mean ± SE. The significance of the differences between the values performed by a one-way ANOVA test and Dunnett's Multiple Comparison Test using GraphPad Prism software. $P < 0.05$ was considered to be a significant difference.

Results

Estimation of blood glucose levels

The diabetic control group showed a significant increase in BGL compared to the healthy control group. On repeated administration of the bromocriptine (4 mg/kg), cabergoline (0.6 mg/kg) individually or in combination with sarbogrelate a significant ($p < 0.05$) decrease in blood glucose by time compared to the diabetic control group (Table 1).

Kidney hypertrophy index

The results showed that the kidney hypertrophy index significantly increased in the diabetic group of rats compared with the normal control rats. However, the index markedly reduced by both bromocriptine and cabergoline treated groups, even individually or mixed with sarpogrelate (as seen in Table 2). There is no effect of using sarpogrelate on the diabetic kidney index.

Hemodynamic Parameter (Antihypertensive activity)

Alloxan-induced diabetes in rats caused a significant rise in blood pressure after three weeks from the induction of diabetes. Daily oral administration of bromocriptine and cabergoline individually or in combination with sarpogrelate showed a significant decrease in blood pressure (Table 3). There is no effect of sarpogrelate on BP in diabetic rats.

Estimation of Liver and kidney Functions:

The serum concentrations of AST, ALP, urea, and creatinine as an indicator of liver and kidney functions recorded in table 4. Data revealed that the diabetic control group had a significant increase in the

previous biomarkers' serum concentrations compared to the healthy control rats. Daily administration of bromocriptine, cabergoline even alone, or in combination with sarpogrelate caused significantly decreased serum concentrations of the previous biomarkers, comparing to the positive control of diabetic rats. There is no marked effect of sarpogrelate treatment on the previous biochemical indicators in the diabetic rats.

Myocardial biomarkers

Bromocriptine and cabergoline treated animals for one month in doses 10 mg/kg, and 0.6 mg/kg respectively displayed significant elevation of LDH-1 level in the serum. By contrast, using a combination of bromocriptine and cabergoline with sarpogrelate treatment significantly decreases the level of the biomarkers in the serum. The results in table 5 indicated that the qualitative test of troponin I reagent kit showed only positive results with bromocriptine and cabergoline treated groups. The results of the ELISA test indicate that the expression levels of TNF-alpha 1 in the diabetic rats' groups treated with bromocriptine or cabergoline individually were significantly higher comparing to the diabetic control rats. The groups of combination between bromocriptine and cabergoline with sarpogrelate showed lower TNF-alpha 1 expression levels comparing to the groups treated with bromocriptine or cabergoline individually (Table 5).

Evaluation of myocardial injury

Myocardial infarction size was used as an indicator of the progress of the myocardial injury. The hearts of bromocriptine 4 mg/kg, and cabergoline 0.6 mg/kg treated groups showed a significant increase in risk area infarction. By contrast, the combination of bromocriptine or cabergoline with sarpogrelate (50 mg/kg) reduced the percentage of the myocardial infarct size (Figures 1A, 1B).

Discussion

Both bromocriptine and cabergoline induced hypoglycemic activity may be due to enhanced suppressive hepatic glucose production [33]. The exact mechanism of action as antidiabetic is not entirely identified; bromocriptine decrease hepatic production of glucose, increase glucose transporter production, or increase or mimic glucagon-like peptide-1 activity [34]. Its contribution to hypoglycemia may be due to adjustments in the neural control of seasonal and patterns of food intake and nutrient storage [35]. Bromocriptine was approved by the Food and Drug Administration (FDA) in May 2009 for the treatment of type 2 diabetes.

In the present study, diabetic nephropathy is the most common cause of renal complication and the leading of hypertension. Both bromocriptine and cabergoline showed a marked antihypertensive activity, which agrees with some previous reports [36, 37]. This action related to dopamine D2 receptors acting drugs, which can lower the blood pressure by inhibition of Na/k ATPase activity, vasodilation, and inhibition of sympathetic nerve activity. Both bromocriptine and cabergoline induced a marked improvement in the kidney function by decreasing urea and creatinine serum levels. The pharmacological

pathways that explain this effect have not been sufficiently determined. The result agrees with some of the previous studies suggest that the development of therapies directed to increase renal D₂ receptor expression/function may provide novel and practical approaches in the treatment of renal injury [38].

The high noted adverse effect of bromocriptine and cabergoline on heart represented in myocardial injury and infarction approved in the present study by using relative overdoses for a month of treatment manner. The action may be related to dopamine D₂ and serotonin 5-HT (2A) receptors agonistic properties, increasing the heart pumping rate. It has been reported that both bromocriptine and cabergoline (ergot derivative) have been associated with heart disease since the two drugs have both dopamine D₂ and serotonin 5-HT (2A) receptors agonistic properties [17, 18]. It is hypothesized that one component of the serotonin system, the 5-HT_{2A} receptor, is a common and contributing factor underlying aspects of cardiovascular disorders and 5-HT_{2A} receptors have been linked to vasoconstriction, and to inflammatory processes [39] and vasodilation through activating nitric oxide (NO) synthase (NOS) via serotonin 5-HT (1B) receptors in endothelial cells, possesses different effects on regulating vascular tone. These facts lead to consider that sarpogrelate, a 5-HT(2A) receptor blocker, may increase coronary blood flow via either attenuation of vasoconstriction through 5HT(2A) receptor blockade or of vasodilation by relative stimulation of NOS through 5-HT1B receptor [40].

According to the current observed data, the combination of bromocriptine and cabergoline with the new chemical agent sarpogrelate (selective 5HT2a/2b antagonists) decreases the adverse effects of these two drugs on the heart. The protective effects of sarpogrelate on myocardial tissue were approved by its ability to decrease the secretion of myocardial biomarkers. As shown by decreasing LDH-1, Troponin I, and TNF alpha 1 during the treatment of bromocriptine and cabergoline. Sarpogrelate attenuates cardiac dysfunction, infarct size; these results support the view said that serotonin and 5-HT (2A) might contribute to the harmful effects of ischemic injury in the heart. Regarding the biochemical study, sarpogrelate drug can be considered a safe drug on liver and kidney functions.

Conclusions

According to the given study, both bromocriptine and cabergoline can be used safely in combination with sarpogrelate for the treatment of many diseases like hypertension, diabetes, and Parkinsonism. Thus, we hypothesize that sarpogrelate deserves additional experimental and clinical research related to cardiovascular diseases.

Abbreviations

ALT
Alanine Aminotransferase
AST
Aspartate Aminotransferase
TNF

Tumor necrosis factor
TTC
Triphenyl tetrazolium chloride
LDH
Lactate dehydrogenase

Declarations

Ethics approval and consent to participate:

The study was approved in December 2019 by the ethical committee of research of Batterjee medical college. The committee consists of four people. The research protocol and the study plan were submitted. The committee held a comprehensive discussion of risks and benefits before reaching the approval conclusion. During the study, the research coordinator of the ethics committee updated the progress of the research. In addition, the research experiments on animals followed the guidelines of the experimental animals' research and ethics committee "EAREC", King Abdulaziz University.

Consent for publication

Not applicable

Availability of data and materials

Not applicable

Competing interests

No competing interests

Funding

There was no funding available for the current manuscript submitted.

Authors' contributions

All authors conceived and planned the experiments. MF carried out the implementation of the experiments. RM planned and carried out the statistical analyses and contributed to sample preparation.

MF took the lead in writing the manuscript. All authors contributed to the interpretation of the results, provided critical feedback and helped shape the research, analysis, and manuscript.

Acknowledgments

I would like to express my sincere gratitude to my advisor Prof. Hekma Abdul Latif, for her continuous support of my Ph.D. research, for his patience, motivation, and immense knowledge. I would like to thank the rest of my thesis committee: Assistant Prof. May Galal, Assistant Prof. Mohamed Elyammany, for their encouragement, insightful comments. My sincere thanks also go to Dr. Iklas Sindi, Batterjee medical college, for offering me the opportunities to work on this project in the college laboratories.

References

1. Koya D, et al. "Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats". *J Am Soc Nephrol*. 2003;14:250–3.
2. Debnam ES, Unwin RJ. "Hyperglycemia and intestinal and renal glucose transport: implications for diabetic renal injury". *Kidney Int*. 1996;50:1101–9.
3. Fridlyand LE, Philipson LH. "Oxidative reactive species in cell injury: mechanisms in diabetes mellitus and therapeutic approaches". *Ann N Y Acad Sci*. 2005;1066:136–15.
4. Sevindik M. "Antioxidant activity of ethanol extract of *Daedaleopsis nitida* medicinal mushroom from Turkey". *Mycopath*. 2018;16:47–9.
5. Sevindik M. "Wild Edible Mushroom *Cantharellus cibarius* as a Natural Antioxidant Food". *Turkish Journal of Agriculture-Food Science Technology*. 2019;7:1377–81.
6. 10.2337/dc11-0064
DeFronzo RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes [published correction appears in *Diabetes Care*. 2011;34:1442. Dosage error in article text]. *Diabetes Care*. 2011;34(4):789–794. DOI:10.2337/dc11-0064.
7. Shivaprasad C, Kalra S. Bromocriptine in type 2 diabetes mellitus. *Indian J Endocrinol Metab*. 2011;15:17–24. DOI:10.4103/2230-8210.83058.
8. Narkar V, Kunduzova O, Hussain T, Cambon C, Parini A, Lokhandwala M. Dopamine D2-like receptor agonist bromocriptine protects against ischemia/reperfusion injury in rat kidney. *Kidney Int*. 2004;66:633–40. DOI:10.1111/j.1523-1755.2004.00783.x.
9. Oliva Mejía-Rodríguez JE, Herrera-Abarca GCeballos-Reyes, Avila-Diaz M. Carmen Prado-Uribe, Francisco Belio-Caro, Antonio Salinas-González, Helios Vega-Gomez, Cleto Alvarez-Aguilar, Bengt Lindholm, Elvia García-López, and Ramón Paniagua. "Cardiovascular and Renal Effects of Bromocriptine in Diabetic Patients with Stage 4 Chronic Kidney Disease". *Biomed Res Int*. 2013. Doi.org/10.1155/2013/104059. Article ID 104059.

10. Lahlou S, Duarte GP. Hypotensive action of bromocriptine in the DOCA-salt hypertensive rat: contribution of spinal dopamine receptors. *Fundam Clin Pharmacol*. 1998;12:599–606. DOI:10.1111/j.1472-8206.1998.tb00992.x.
11. Luchsinger A, Grilli M, Velasco M. Metoclopramide, and domperidone block the antihypertensive effect of bromocriptine in hypertensive patients. *Am J Ther*. 1998;5:81–8. DOI:10.1097/00045391-199803000-00005.
12. Mokhles M., et al. "Dopamineagonist and heart failure in patients with Parkinson's disease: a nested case-control study on multiple health care databases". in *Proceedings of the European Society of Cardiology Congress, Stockholm, Sweden, 2010*.
13. Bordet R. [Central dopamine receptors: general considerations (Part 1)]. *Rev Neurol (Paris)*. [Article in French]. 2004; 160:862–870.
14. Melmed S, Braunstein GD, Chang RJ, Becker DP. Pituitary tumors secreting growth hormone and prolactin. *Ann Intern Med*. 1986;105:238–53.
15. Louis CS, Tan, Kenneth KC, Ng W-L, Au, Raymond KK, Lee Y-H, Chan, Nigel CK, Tan. Bromocriptine use and the risk of valvular heart disease. *Movement disorders*. 2009;24:344–9.
16. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. *Eur J Endocrinol*. 2008;159:R11–4. DOI:10.1530/EJE-08-0365.
17. Kekewska A, Hübner H, Gmeiner P, Pertz HH. The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT_{2A} and 5-HT_{2B} receptors and thus is a determinant of valvular heart disease. *J Pharmacol Exp Ther*. 2011;338:381–91. DOI:10.1124/jpet.111.181255.
18. Oana F, Onozuka H, Tsuchioka A, et al. Function and expression differences between ergot and non-ergot dopamine D₂ agonists on heart valve interstitial cells. *J Heart Valve Dis*. 2014;23:246–52.
19. Brasil D, Temsah RM, Kumar K, Kumamoto H, Takeda N, Dhalla NS. Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats. *J Cardiovasc Pharmacol Ther*. 2002;7:53–9. DOI:10.1177/107424840200700i108.
20. Satomura K, Takase B, Hamabe A, et al. Sarpogrelate, a specific 5HT₂-receptor antagonist, improves the coronary microcirculation in coronary artery disease. *Clin Cardiol*. 2002;25:28–32. DOI:10.1002/clc.4950250108.
21. Saini HK, Takeda N, Goyal RK, et al. Therapeutic potentials of sarpogrelate in cardiovascular disease. *Cardiovasc Drug Rev*. 2004;22:27–54. DOI:10.1111/j.1527-3466.2004.tb00130.x.
22. Kanter M, Coskun O, Korkmaz A, Oter S. Effects of *Nigella sativa* on oxidative stress and beta-cell damage in streptozotocin-induced diabetic rats. *Anat Rec A Discov Mol Cell Evol Biol*. 2004;279:685–91. DOI:10.1002/ar.a.20056.
23. Festing MF, Altman DG. Guidelines for the design and statistical analysis of experiments using laboratory animals. *ILAR J*. 2002;43:24458.
24. Mukherjee KI. "Medical laboratory technology". Tata Mc Graw Hill. 1988;3:991–3.

25. Johns C, et al. "Models of Experimental Hypertension in Mice". *Hypertension*. 1996;28:1064–9.
26. King PRN, King EJ. "Estimation of plasma phosphatase by determination of hydrolyzed phenol with amino antipyrine". *J Clin Path*. 1954;7:322326.
27. Tietz NW, et al. "In Tietz Textbook of Clinical Chemistry. Ed. Burtis CA, Ashwood ER. pp. 1354–74. W. B. Saunders Company, London, 1994.
28. Kaplan A. "Urea nitrogen and urinary ammonia. In: Standard Method of Clinical Chemistry". Ed. Meites S. New York: Academic Press Inc.; 1965. pp. 245–56.
29. Niellands JB. "In Methods in Enzymology". p. 449. Ed. by Colowick, S. P. & Kaplan, N. O. New York: Academic Press Inc., 1955.
30. Fishbein MC, et al. "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique". *Am Heart J*. 1981;101:593–600.
31. Nachlas M, Schnitka T. "Macroscopic identification of early myocardial infarcts by alterations in dehydrogenase activity". *AmJPathol*. 1963;42:379–406.
32. Curtis MJ, et al. "Experimental design and analysis and their reporting: new guidance for publication in BJP". *Br J Pharmacol*. 2015;172:3461–71.
33. Defronzo RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. *Diabetes Care*. 2011;34:789–94. doi:10.2337/dc11-0064.
34. Scranton R, Cincotta A. Bromocriptine—unique formulation of a dopamine agonist for the treatment of type 2 diabetes. *Expert Opin Pharmacother*. 2010;11:269–79. doi:10.1517/14656560903501544.
35. Aminorroaya A, Janghorbani M, Ramezani M, Haghighi S, Amini M. Does bromocriptine improve glycemic control of obese type-2 diabetics? *Horm Res*. 2004;62:55–9. doi:10.1159/000078932.
36. Zeng C, et al. "The dopaminergic system in hypertension". *Clin Sci (Lond)*. 2007;112:583–97.
37. McCoy CE, et al. "Selective antagonism of the hypotensive effects of dopamine agonists in spontaneously hypertensive rats". *Hypertension*. 1986;8:298–302.
38. Konkalmatt PR, Asico LD, Zhang Y, et al. Renal rescue of dopamine D2 receptor function reverses renal injury and high blood pressure. *JCI Insight*. 2016;1:e85888. doi:10.1172/jci.insight.85888.
39. 10.1155/2009/475108
Nichols CD. Serotonin 5-HT(2A) Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases. *Cardiovasc Psychiatry Neurol*. 2009; 2009:475108. doi:10.1155/2009/475108.
40. Fujita M, Minamino T, Sanada S, et al. Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts. *J Mol Cell Cardiol*. 2004;37:1219–23. doi:10.1016/j.yjmcc.2004.09.016.

Tables

Table 1: Effect of the tested drugs on BGL in alloxan-induced diabetic rats.

BGL mg/dL				
Groups	week 1	week 2	week 3	week 4
Normal control group	136.5 ± 18.52	121.33 ± 12.08	119.25 ± 11.35	109 ± 10.92
Diabetic control group	359.75 ± 45.13*	328 ± 141.34*	428.5 ± 121.17*	396.5 ± 80.60*
Diabetic group treated with Bromocriptine	191 ± 16.89 [#]	199.25 ± 65.05 [#]	238.25 ± 56.88 [#]	284.25 ± 148.00 [#]
Diabetic group treated with Cabergoline	213.75 ± 37.74 [#]	211.75 ± 38.62 [#]	293 ± 213.15 [#]	280.25 ± 220.48 [#]
Diabetic group treated with Sarpogrelate	326.25 ± 93.45	298.25 ± 122.37	393.75 ± 118.77	369.75 ± 43.15
Diabetic group treated with Bromocriptine +sarpogrelate	247.75 ± 50.35 [#]	215.5 ± 33.20 [#]	310.25 ± 70.59 [#]	288.25 ± 109.41 [#]
Diabetic group treated with cabergoline + sarpogrelate	196 ± 54.20 [#]	158.75 ± 35.01 [#]	235.5 ± 182.22 [#]	215.75 ± 141.46 [#]

Values shown are means ± SEM; n = 6 rats per group. * P < 0.05, significantly different from normal control group; # P < 0.05, significantly different from diabetic control group.

Table 2: Effect of the tested drugs on Kidney Hypertrophic Index in alloxan-induced diabetic rats.

Kidney Hypertrophic Index	
Groups	KHI (g/g * 1000)
Normal control group	4.555 ± 0.423
Diabetic control group	6.6125 ± 0.57*
Diabetic group treated with Bromocriptine	4.7475 ± 0.33 [#]
Diabetic group treated with Cabergoline	4.81 ± 0.49 [#]
Diabetic group treated with Sarpogrelate	5.90 ± 0.27
Diabetic group treated with Bromocriptine +sarpogrelate	4.715 ± 0.61 [#]
Diabetic group treated with cabergoline + sarpogrelate	4.46 ± 0.48 [#]

Values shown are means \pm SEM; n = 6 rats per group. * P < 0.05, significantly different from normal control group; # P < 0.05, significantly different from diabetic control group.

Table3: Effect of the tested drugs on mean blood pressure in alloxan-induced diabetic rats.

Mean Blood pressure MBP (mmHg)				
Groups	week 1	week 2	week 3	week 4
Normal control group	110 \pm 4.01	118.25 \pm 8.99	108.75 \pm 4.57	111.5 \pm 4.20
Diabetic control group	112.5 \pm 9.14	121.75 \pm 11.35	150.75 \pm 5.25*	151.25 \pm 5.12*
Diabetic group treated with Bromocriptine	115 \pm 9.12	102.75 \pm 6.8	109 \pm 10.23#	121.75 \pm 15.26#
Diabetic group treated with Cabergoline	103.75 \pm 7.0	105.5 \pm 9.14	123 \pm 7.87#	107.75 \pm 107.75#
Diabetic group treated with Sarpogrelate	118.75 \pm 10.87	114.75 \pm 8.53	137.75 \pm 8.53	139 \pm 18.56
Diabetic group treated with Bromocriptine +sarpogrelate	104.5 \pm 7.59	104.75 \pm 4.99	106.25 \pm 11.08#	118 \pm 13.03#
Diabetic group treated with cabergoline + sarpogrelate	109.25 \pm 11.58	105 \pm 9.05	106 \pm 18.3#	104.25 \pm 5.5#

Values shown are means \pm SEM; n = 6 rats per group. * P < 0.05, significantly different from normal control group; # P < 0.05, significantly different from diabetic control group.

Table 4: Effect of the tested drugs on liver and kidney functions in alloxan-induced diabetic rats after 4 weeks.

BIOCHEMICALS				
Group	ALP(IU/L)	AST(IU/L)	Urea (mmol/L)	Creatinine (mmol/L)
Normal control group	60.85±8.77	25.04±4.96	43.38±4.77	0.46 ± 0.07
Diabetic control group	89.05±10.44*	45.86±7.57*	75.81±18.85*	1.89 ± 0.19*
Diabetic group treated with Bromocriptine	68.83±7.27 [#]	34.18±5.78 [#]	60.41±6.22 [#]	1.04 ± 0.26 [#]
Diabetic group treated with Cabergoline	73.27±7.93 [#]	21.37±10.05 [#]	52.09±2.23 [#]	0.79 ± 0.11 [#]
Diabetic group treated with Sarpogrelate	82.16±23.83	41.47±10.02	69.41±7.65	1.68 ± 0.25
Diabetic group treated with Bromocriptine +sarpogrelate	64.8±7.21 [#]	31.03±6.44 [#]	44.4±8.23 [#]	1.26 ±0.25 [#]
Diabetic group treated with cabergoline + sarpogrelate	73.44±6.68 [#]	33.79±11.18 [#]	51.16±10.43 [#]	1.33 ± 0.21 [#]

Values shown are means ± SEM; n = 6 rats per group. * P < 0.05, significantly different from normal control group; # P < 0.05, significantly different from diabetic control group.

Table 5: Effect of the tested drugs on Lactate dehydrogenase-1 and TNFα1 in alloxan-induced diabetic rats.

BIOCHEMICALS			
Group	LDH (IU/L)	TNFa1 (pg/mL)	
Normal control group	17.42± 0.69	06.12±0.45	
Diabetic control group	18.50 ± 1.53	08.32 ±0.56	
Diabetic group treated with Bromocriptine	40.50 ± 10.69 [#]	36.56 ±2.32 [#]	
Diabetic group treated with Cabergoline	36.86 ±12.47 [#]	31.20 ±4.23 [#]	
Diabetic group treated with Sarpogrelate	19.55 ± 2.20	09.74 ±0.98	
Diabetic group treated with Bromocriptine +sarpogrelate	27.75 ± 3.91 ^a	14.84 ±1.23 ^a	
Diabetic group treated with cabergoline + sarpogrelate	34.57 ±6.60 ^b	08.59 ±0.76 ^b	

Values shown are means ± SEM; n = 6 rats per group. # P < 0.05, significantly different from diabetic control group. a P < 0.05, significantly different from diabetic group treated with bromocriptine. b P < 0.05, significantly different from diabetic group treated with cabergoline.

Figures




Figure 1

A: Effect of the tested drugs in alloxan-induced diabetic mice after 4 weeks of treatment. (A) Diabetic control rats, (B) Bromocriptine treated group, (C) Cabergoline treated group, (D) Bromocriptine+

Sarbogrelate treated group, (E) Cabergoline+ Sarbogrelate treated group, (F) Cabergoline+ domperidone treated group. B: Effect of the tested drugs on percentage of myocardial infarct size in alloxan-induced diabetic rats. Values shown are means \pm SEM; n = 6 rats per group. # P < 0.05, significantly different from diabetic control group. a P < 0.05, significantly different from diabetic group treated with bromocriptine. b P < 0.05, significantly different from diabetic group treated with cabergoline